X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PANACEA BIOTECH - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PANACEA BIOTECH GSK PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 64.9 142.3 45.6% View Chart
P/BV x 10.4 3.2 330.0% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
PANACEA BIOTECH
Mar-14
GSK PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,838149 2,581.0%   
Low Rs2,63782 3,204.1%   
Sales per share (Unadj.) Rs354.284.1 420.9%  
Earnings per share (Unadj.) Rs39.8-18.3 -217.2%  
Cash flow per share (Unadj.) Rs42.9-6.7 -640.0%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.983.7 283.0%  
Shares outstanding (eoy) m84.7061.25 138.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.11.4 665.9%   
Avg P/E ratio x81.4-6.3 -1,290.5%  
P/CF ratio (eoy) x75.5-17.2 -438.0%  
Price / Book Value ratio x13.71.4 990.3%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2167,074 3,876.2%   
No. of employees `0004.72.8 170.8%   
Total wages/salary Rs m4,8301,449 333.3%   
Avg. sales/employee Rs Th6,387.01,874.1 340.8%   
Avg. wages/employee Rs Th1,028.3527.0 195.1%   
Avg. net profit/employee Rs Th717.1-407.7 -175.9%   
INCOME DATA
Net Sales Rs m30,0005,154 582.1%  
Other income Rs m728100 729.7%   
Total revenues Rs m30,7285,254 584.9%   
Gross profit Rs m4,190-766 -546.8%  
Depreciation Rs m263711 37.0%   
Interest Rs m01,503 0.0%   
Profit before tax Rs m4,655-2,881 -161.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m4571,771 25.8%   
Tax Rs m1,74417 10,381.0%   
Profit after tax Rs m3,368-1,121 -300.4%  
Gross profit margin %14.0-14.9 -93.9%  
Effective tax rate %37.5-0.6 -6,423.7%   
Net profit margin %11.2-21.8 -51.6%  
BALANCE SHEET DATA
Current assets Rs m16,7423,810 439.4%   
Current liabilities Rs m7,2028,365 86.1%   
Net working cap to sales %31.8-88.4 -36.0%  
Current ratio x2.30.5 510.4%  
Inventory Days Days52156 33.3%  
Debtors Days Days2167 30.9%  
Net fixed assets Rs m8,63514,480 59.6%   
Share capital Rs m84761 1,381.7%   
"Free" reserves Rs m19,222903 2,128.4%   
Net worth Rs m20,0695,127 391.4%   
Long term debt Rs m105,832 0.2%   
Total assets Rs m30,03819,433 154.6%  
Interest coverage xNM-0.9-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.00.3 376.6%   
Return on assets %11.22.0 570.9%  
Return on equity %16.8-21.9 -76.7%  
Return on capital %25.53.6 700.2%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m5281,539 34.3%   
Fx outflow Rs m7,193942 763.6%   
Net fx Rs m-6,665597 -1,116.0%   
CASH FLOW
From Operations Rs m2,360599 393.9%  
From Investments Rs m3,008-438 -686.9%  
From Financial Activity Rs m-5,108-303 1,687.9%  
Net Cashflow Rs m260-141 -184.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.6 1,700.0%  
FIIs % 23.8 1.3 1,830.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   102,036 10,259 994.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 18, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS